Article
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
Cancer discovery - 12 Jan 2024
Suehnholz Sarah P, Nissan Moriah H, Zhang Hongxin, Kundra Ritika, Nandakumar Subhiksha, Lu Calvin, Carrero Stephanie, Dhaneshwar Amanda, Fernandez Nicole, Xu Benjamin W, Arcila Maria E, Zehir Ahmet, Syed Aijazuddin, Brannon A Rose, Rudolph Julia E, Paraiso Eder, Sabbatini Paul J, Levine Ross L, Dogan Ahmet, Gao Jianjiong, Ladanyi Marc, Drilon Alexander, Berger Michael F, Solit David B, Schultz Nikolaus, Chakravarty Debyani
Abstract excerpt
There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which molecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two temporally distinct versions of the OncoKB knowledge...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.